Emerging MedTech Sebia is recognized as a top emerging MedTech company in India and has ongoing collaborations, presenting a target market opportunity for expansion of diagnostics solutions and lab automation partnerships through distributor channels and co-marketing.

Multiple Myeloma Focus Strong emphasis on multiple myeloma diagnostics and monitoring, including MRD and M-inSight offerings, suggesting upsell potential for high-throughput automation and integrated data workflows in hematology labs.

Automated Capillary Capillary electrophoresis systems (CAPILLARYS 3 family) with walkaway high-throughput capabilities position Sebia for labs seeking streamlined workflows; potential cross-sell of reagents, automation software, and service contracts to expand installed bases.

Autoimmune Testing Autoimmune and infectious disease assay platforms (ELISA, IFA, Alegria 2, dIFine P30) open opportunities to partner on complementary panels, digital imaging interpretation, and bundled testing solutions for reference labs.

Expansion & Partnerships Recent office expansions in the United States and collaborations with diagnostic providers indicate readiness to scale, offering channel partnerships, regional support deals, and joint marketing to accelerate penetration in North America and India.